- Home
- CRUS vs NUVL Comparison
CRUS vs NUVL Comparison
Compare CRUS & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRUS
- NUVL
- Stock Information
- Founded
- CRUS 1984
- NUVL 2017
- Country
- CRUS United States
- NUVL United States
- Employees
- CRUS N/A
- NUVL N/A
- Industry
- CRUS Semiconductors
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- CRUS Technology
- NUVL Health Care
- Exchange
- CRUS Nasdaq
- NUVL Nasdaq
- Market Cap
- CRUS 5.9B
- NUVL 6.5B
- IPO Year
- CRUS 1989
- NUVL 2021
- Fundamental
- Price
- CRUS $132.65
- NUVL $99.32
- Analyst Decision
- CRUS Strong Buy
- NUVL Strong Buy
- Analyst Count
- CRUS 4
- NUVL 12
- Target Price
- CRUS $127.50
- NUVL $123.33
- AVG Volume (30 Days)
- CRUS 435.5K
- NUVL 573.5K
- Earning Date
- CRUS 11-04-2025
- NUVL 10-30-2025
- Dividend Yield
- CRUS N/A
- NUVL N/A
- EPS Growth
- CRUS 18.67
- NUVL N/A
- EPS
- CRUS 6.40
- NUVL N/A
- Revenue
- CRUS $1,929,323,000.00
- NUVL N/A
- Revenue This Year
- CRUS N/A
- NUVL N/A
- Revenue Next Year
- CRUS $5.49
- NUVL N/A
- P/E Ratio
- CRUS $20.72
- NUVL N/A
- Revenue Growth
- CRUS 4.52
- NUVL N/A
- 52 Week Low
- CRUS $75.83
- NUVL $55.54
- 52 Week High
- CRUS $136.92
- NUVL $104.90
- Technical
- Relative Strength Index (RSI)
- CRUS 60.55
- NUVL 62.23
- Support Level
- CRUS $130.51
- NUVL $90.00
- Resistance Level
- CRUS $136.92
- NUVL $104.90
- Average True Range (ATR)
- CRUS 3.57
- NUVL 5.19
- MACD
- CRUS 0.27
- NUVL 0.53
- Stochastic Oscillator
- CRUS 77.08
- NUVL 72.49
About CRUS Cirrus Logic Inc.
Cirrus Logic Inc is a provider of integrated circuits for audio and voice signal processing applications. The firm's products are organized into two streams: portable audio products, and HPMS Products. These products include aAmplifiers, codecs, smart codecs, analog-to-digital converters, digital-to-analog converters and standalone digital signal processors, Camera controllers, haptics and sensing solutions, and battery and power ICs. Roughly half of the firm's revenue is generated in China, with the rest coming from the United States, Europe, South Korea, and countries across the world.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.